Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:8567 |
Name | Hodgkin's lymphoma |
Definition | A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell. |
Source | DiseaseOntology.org |
Alt Ids | DOID:8953 DOID:0060059 DOID:8710 DOID:8652 DOID:8685 DOID:8671 DOID:9107 DOID:8715 DOID:8841 DOID:9096 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma Hodgkin's lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00513474 | Phase I | Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | Completed | USA | 0 |
NCT00576654 | Phase I | Irinotecan Veliparib | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT00602693 | Phase I | Sirolimus Allopurinol + Cyclophosphamide + Fludarabine | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | USA | 0 |
NCT00838955 | Phase II | Temsirolimus | Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT00857389 | Phase II | Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate | Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | Completed | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT01032148 | Phase I | Panobinostat | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT01076543 | Phase Ib/II | Lenalidomide + Temsirolimus | Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01169636 | Phase Ib/II | Panobinostat Pegfilgrastim Carboplatin + Etoposide + Ifosfamide | Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | Completed | USA | 0 |
NCT01196208 | Expanded access | Brentuximab vedotin | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 | No longer available | USA | ROU | POL | ITA | HUN | GBR | FRA | ESP | DEU | CHE | BGR | BEL | AUS | 2 |
NCT01251575 | Phase II | Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus | Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | DNK | 0 |
NCT01333046 | Phase I | MultiTAA-specific T cells Azacitidine + MultiTAA-specific T cells | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (TACTAL) | Active, not recruiting | USA | 0 |
NCT01476839 | Phase I | Basiliximab + Carmustine + Cytarabine + Etoposide + Melphalan + Yttrium Y 90 Basiliximab | Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT01592370 | Phase Ib/II | Nivolumab Daratumumab + Nivolumab Daratumumab Ipilimumab + Nivolumab Daratumumab + Dexamethasone + Nivolumab + Pomalidomide Lirilumab + Nivolumab | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | Completed | USA | POL | ITA | GRC | FRA | BEL | 0 |
NCT01609816 | Phase Ib/II | Dasatinib | Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant | Terminated | USA | 0 |
NCT01621477 | Phase II | Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | Terminated | USA | 0 |
NCT01701986 | Phase Ib/II | Tacrolimus Rituximab Filgrastim Mycophenolate mofetil anti-thymocyte globulin Busulfan + Clofarabine + Gemcitabine | Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas | Completed | USA | 0 |
NCT01716806 | Phase II | Brentuximab vedotin + Nivolumab Bendamustine + Brentuximab vedotin Brentuximab vedotin + Dacarbazine Brentuximab vedotin | A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL) | Completed | USA | CAN | 0 |
NCT01742988 | Phase Ib/II | Bendamustine + CUDC-907 + Rituximab CUDC-907 + Rituximab CUDC-907 CUDC-907 + Venetoclax | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | Completed | USA | 0 |
NCT01745354 | Phase I | SD-101 | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) | Terminated | USA | 0 |
NCT01811368 | Phase II | anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | Unknown status | USA | 0 |
NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01896999 | Phase I | Brentuximab vedotin + Ipilimumab | Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT01897012 | Phase I | Romidepsin Alisertib | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | Completed | USA | 0 |
NCT01905813 | Phase I | Dezapelisib + Itacitinib Dezapelisib | Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT01949883 | Phase I | CPI-0610 | A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma | Completed | 0 | |
NCT01953692 | Phase I | Pembrolizumab | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) | Completed | 0 | |
NCT01983969 | Phase Ib/II | Rituximab Dexamethasone Busulfan + Melphalan Azacitidine + Gemcitabine + Vorinostat | Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | Completed | USA | 0 |
NCT02018861 | Phase I | Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib | A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies | Completed | USA | 0 |
NCT02061761 | Phase Ib/II | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | Completed | USA | CAN | 0 |
NCT02091063 | Phase Ib/II | Ricolinostat | ACY-1215 for Relapsed/Refractory Lymphoid Malignancies | Terminated | USA | 0 |
NCT02098512 | Phase Ib/II | Brentuximab vedotin | Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | Unknown status | USA | 0 |
NCT02104427 | Phase II | Burixafor Filgrastim | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | Completed | USA | 0 |
NCT02130869 | Phase I | Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT02164006 | Phase I | Umbralisib | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients | Completed | USA | 0 |
NCT02181218 | Phase I | Pegfilgrastim Romidepsin Dexamethasone + Gemcitabine + Oxaliplatin | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | Completed | USA | 0 |
NCT02181738 | Phase II | Nivolumab | Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205) | Completed | USA | NLD | ITA | GBR | ESP | DEU | CZE | CAN | BEL | AUT | 0 |
NCT02200380 | Phase II | Plerixafor CDX-301 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | Terminated | USA | 0 |
NCT02203903 | Phase I | MultiTAA-specific T cells | Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) | Recruiting | USA | 0 |
NCT02208037 | Phase II | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | Completed | USA | 0 | |
NCT02227199 | Phase Ib/II | Brentuximab vedotin + Carboplatin + Etoposide + Ifosfamide | Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE) | Active, not recruiting | USA | 0 |
NCT02254239 | Phase I | Everolimus | Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | Terminated | USA | 0 |
NCT02287311 | Phase I | LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | Recruiting | USA | 0 |
NCT02304458 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Completed | USA | CAN | 0 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | GBR | 0 |
NCT02332668 | Phase Ib/II | Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | Recruiting | USA | SWE | NLD | ITA | ISR | GBR | FRA | DEU | BRA | 1 |
NCT02343666 | Phase I | Filgrastim Carmustine Plerixafor O6-benzylguanine | HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection | Withdrawn | USA | 0 |
NCT02362997 | Phase II | Pembrolizumab | Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL | Completed | USA | 0 |
NCT02376699 | Phase I | Pembrolizumab + SEA-CD40 SEA-CD40 | Safety Study of SEA-CD40 in Cancer Patients | Terminated | USA | 0 |
NCT02398240 | Phase II | Brentuximab vedotin + Doxorubicin + Rituximab + Vincristine Sulfate Brentuximab vedotin + Doxorubicin + Vincristine Sulfate | Brentuximab for Newly Diagnosed Hodgkin Disease | Completed | USA | 0 |
NCT02408042 | Phase Ib/II | Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | Withdrawn | USA | 0 |
NCT02429375 | Phase Ib/II | Brentuximab vedotin + Mocetinostat | Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma | Completed | USA | 0 |
NCT02453594 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) | Completed | 0 | |
NCT02541604 | Phase I | Atezolizumab | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors | Terminated | USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | 0 |
NCT02572167 | Phase Ib/II | Brentuximab vedotin + Nivolumab | A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | Completed | USA | 0 |
NCT02576496 | Phase I | Tinostamustine | Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | Completed | USA | NLD | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02595866 | Phase I | Pembrolizumab | Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms | Completed | USA | 0 |
NCT02603419 | Phase I | Avelumab | Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) | Terminated | USA | ITA | GBR | 0 |
NCT02613598 | Phase I | Bortezomib + Ruxolitinib | Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | Completed | USA | 0 |
NCT02624258 | Phase I | RNA CART19 cells | Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma | Terminated | USA | 0 |
NCT02651662 | Phase I | Cemiplimab Cemiplimab + Odronextamab | Study of REGN2810 and REGN1979 in Patients With Lymphoma | Recruiting | USA | POL | ISR | ESP | DEU | 0 |
NCT02661503 | Phase III | Brentuximab vedotin + Cyclophosphamide + Dacarbazine + Dexamethasone + Doxorubicin + Etoposide Bleomycin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Procarbazine + Vincristine Sulfate | HD21 for Advanced Stages | Active, not recruiting | DEU | 0 |
NCT02663297 | Phase I | ATLCAR.CD30 cells | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | Active, not recruiting | USA | 0 |
NCT02665650 | Phase I | AFM13 + Pembrolizumab | Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | Completed | USA | ESP | 0 |
NCT02684292 | Phase III | Brentuximab vedotin Pembrolizumab | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) | Active, not recruiting | 0 | |
NCT02690545 | Phase Ib/II | ATLCAR.CD30 cells | Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | Recruiting | USA | 0 |
NCT02701673 | Phase Ib/II | Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan | Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | Withdrawn | 0 | |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Active, not recruiting | USA | 0 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT02744612 | Phase II | Brentuximab vedotin + Ibrutinib | Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02758717 | Phase II | Brentuximab vedotin + Nivolumab | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02763254 | Phase II | CMD-003 | Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC) | Terminated | USA | 0 |
NCT02797470 | Phase Ib/II | Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT02824029 | Phase II | Ibrutinib | Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02867618 | Phase Ib/II | Carfilzomib + Umbralisib | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | Terminated | USA | 0 |
NCT02869633 | Phase II | Ibrutinib | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT02875067 | Phase Ib/II | Lenalidomide + Pembrolizumab | Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma | Terminated | USA | 0 |
NCT02890758 | Phase I | Nogapendekin alfa inbakicept | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Completed | USA | 0 |
NCT02917083 | Phase I | ATLCAR.CD30 cells + Cyclophosphamide + Fludarabine | CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (RELY-30) | Recruiting | USA | 0 |
NCT02927769 | Phase II | Brentuximab vedotin + Nivolumab Bendamustine + Brentuximab vedotin | A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744) | Completed | USA | POL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CZE | CAN | 0 |
NCT02931110 | Phase I | CBL0137 | Study of IV CBL0137 in Previously Treated Hematological Subjects | Terminated | USA | 0 |
NCT02940301 | Phase II | Ibrutinib + Nivolumab | Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT02961816 | Phase II | Pyridoxine Busulfan + Gemcitabine + Melphalan + Panobinostat Dexamethasone + Filgrastim + Palifermin + Rituximab | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma | Withdrawn | 0 | |
NCT02973113 | Phase I | EB-VST cells + Nivolumab | Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE) | Completed | USA | 0 |
NCT03013933 | Phase I | Brentuximab vedotin + Cyclosporine + Verapamil | Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | Completed | USA | 0 |
NCT03015896 | Phase Ib/II | Lenalidomide + Nivolumab | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03016871 | Phase II | Nivolumab Carboplatin + Etoposide + Ifosfamide + Nivolumab | Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL | Active, not recruiting | USA | 0 |
NCT03033914 | Phase I | Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma | Active, not recruiting | USA | CAN | 0 |
NCT03049449 | Phase I | Cyclophosphamide + Fludarabine 5F11-28Z CAR-T cells | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Completed | USA | 0 |
NCT03057795 | Phase II | Brentuximab vedotin + Nivolumab | Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03077828 | Phase II | Carboplatin + Etoposide + Ifosfamide + Pembrolizumab | Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03120676 | Phase II | Atezolizumab | Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma | Terminated | USA | 0 |
NCT03138499 | Phase III | Brentuximab vedotin Brentuximab vedotin + Nivolumab | Phase III Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, | Terminated | USA | 2 |
NCT03150329 | Phase I | Pembrolizumab + Vorinostat | Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03179917 | Phase II | Pembrolizumab | Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03179930 | Phase II | Entinostat + Pembrolizumab | Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas | Active, not recruiting | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03226249 | Phase II | Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine | PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03233347 | Phase II | Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine | Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03236935 | Phase I | L-NMMA + Pembrolizumab | Phase Ib of L-NMMA and Pembrolizumab | Active, not recruiting | USA | 0 |
NCT03259503 | Phase Ib/II | Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab | Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas | Active, not recruiting | USA | 0 |
NCT03331341 | Phase II | Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine | Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03331731 | Phase II | Pembrolizumab | A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma (PLIMATH) | Active, not recruiting | NZL | AUS | 0 |
NCT03337919 | Phase II | Nivolumab | ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (ANIMATE) | Active, not recruiting | GBR | 0 |
NCT03357757 | Phase II | Avelumab + Valproic acid | Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) | Active, not recruiting | CAN | 0 |
NCT03407144 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Pembrolizumab + Prednisone + Vincristine Sulfate Bleomycin + Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | Active, not recruiting | USA | SVK | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CZE | BRA | 5 |
NCT03432741 | Phase I | Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | Suspended | USA | 0 |
NCT03436862 | Phase II | Nivolumab | Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression | Completed | USA | 0 |
NCT03471351 | Phase Ib/II | Pembrolizumab + Tenalisib | Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL | Terminated | USA | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Active, not recruiting | USA | 0 |
NCT03495713 | Phase II | Nivolumab | RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS | Terminated | USA | 0 |
NCT03517137 | Phase II | Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab | Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study (COBRA) | Active, not recruiting | SVK | POL | NLD | ESP | DNK | BEL | 1 |
NCT03580408 | Phase II | Nivolumab + Vinblastine Nivolumab | Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma | Completed | FRA | BEL | 0 |
NCT03598608 | Phase Ib/II | MK-4280 + Pembrolizumab | Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | Recruiting | USA | ITA | ISR | DEU | CAN | AUS | 0 |
NCT03602157 | Phase I | ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | Recruiting | USA | 0 |
NCT03617666 | Phase II | Avelumab | Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study (AVENuE) | Active, not recruiting | GBR | AUS | 0 |
NCT03618550 | Phase II | Doxorubicin + Gemcitabine + Pembrolizumab + Vinorelbine | Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03646123 | Phase II | Brentuximab vedotin + Dacarbazine + Doxorubicin + Filgrastim + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | Terminated | USA | POL | ITA | ESP | CZE | AUS | 0 |
NCT03652441 | Phase II | Brentuximab vedotin | Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma | Unknown status | DEU | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT03681561 | Phase Ib/II | Nivolumab + Ruxolitinib | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03697408 | Phase Ib/II | Everolimus + Itacitinib | Itacitinib + Everolimus in Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03712202 | Phase II | Nivolumab Brentuximab vedotin + Nivolumab Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Vinblastine | Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03739606 | Phase II | Flotetuzumab | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Withdrawn | 0 | |
NCT03739619 | Phase Ib/II | Bendamustine + Gemcitabine + Nivolumab | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03755804 | Phase II | Bendamustine + Bleomycin + Doxorubicin + Etoposide + Prednisone + Vinblastine + Vincristine Sulfate | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | Recruiting | USA | 0 |
NCT03776864 | Phase II | Pembrolizumab + Umbralisib | Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | Terminated | USA | 0 |
NCT03778073 | Phase I | Cosibelimab | Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT03809624 | Phase II | INBRX-105 INBRX-105 + Pembrolizumab | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) | Terminated | USA | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
NCT03829254 | Phase Ib/II | NUC-7738 NUC-7738 + Pembrolizumab | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | Recruiting | GBR | 0 |
NCT03843294 | Phase I | MultiTAA-specific T cells + Nivolumab | Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma | Active, not recruiting | USA | 0 |
NCT03885947 | Phase I | Cyclophosphamide + Fludarabine + Thiotepa | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | Completed | USA | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
NCT03907488 | Phase III | Pegfilgrastim Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Filgrastim Dacarbazine + Doxorubicin + Nivolumab + Vinblastine | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | Active, not recruiting | USA | CAN | 1 |
NCT03920631 | Phase I | Nivolumab | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) | Withdrawn | USA | 0 |
NCT03921879 | Phase I | OT-82 | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma | Unknown status | USA | 0 |
NCT03925935 | Phase I | AB-205 | Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation | Completed | USA | 0 |
NCT03947255 | Phase II | Brentuximab vedotin | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma | Terminated | USA | 0 |
NCT03983668 | Phase Ib/II | Pembrolizumab + Vidutolimod | CMP-001 for Relapsed and Refractory Lymphoma | Active, not recruiting | USA | 0 |
NCT04016116 | Phase II | Pembrolizumab + Ruxolitinib Pembrolizumab | Dual PD-1 and JAK2 Inhibition in Hematological Malignancies | Withdrawn | USA | 0 |
NCT04052997 | Phase II | Camidanlumab tesirine | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma | Completed | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | 0 |
NCT04072458 | Phase I | BP1002 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Recruiting | USA | 0 |
NCT04074746 | Phase I | Cyclophosphamide + Fludarabine AFM13 | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT04134325 | Phase I | Nivolumab Pembrolizumab | Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT04160195 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | Terminated | USA | 0 |
NCT04233697 | Phase I | Copanlisib + Romidepsin | Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma | Withdrawn | 0 | |
NCT04254107 | Phase I | SGN-TGT Pembrolizumab + SGN-TGT | A Safety Study of SGN-TGT in Patients With Advanced Cancer | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04318080 | Phase II | Tislelizumab | Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | Completed | USA | AUS | 0 |
NCT04464798 | Phase I | Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | Active, not recruiting | USA | ITA | FRA | DEU | 2 |
NCT04491370 | Phase Ib/II | Polatuzumab vedotin-piiq | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04510636 | Phase II | Bendamustine + Pembrolizumab | Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | Recruiting | CAN | 0 |
NCT04561206 | Phase II | Brentuximab vedotin + Nivolumab | Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed Classical Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04653649 | Phase Ib/II | HSP-CAR30 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | Unknown status | ESP | 0 |
NCT04681105 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | Active, not recruiting | USA | 0 |
NCT04684108 | Phase I | SG301 | SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies | Active, not recruiting | 1 | |
NCT04685616 | Phase III | Brentuximab vedotin + Dacarbazine + Doxorubicin + Filgrastim + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Vinblastine | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (RADAR) | Recruiting | USA | NZL | NLD | GBR | ESP | BEL | AUS | 0 |
NCT04788043 | Phase II | Hu5F9-G4 + Pembrolizumab | Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT04837859 | Phase II | Tislelizumab Dacarbazine + Doxorubicin + Tislelizumab + Vinblastine | Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE) | Recruiting | DEU | 0 |
NCT04838652 | Phase II | Cisplatin + Cytarabine + Dexamethasone + Pembrolizumab Carboplatin + Etoposide + Ifosfamide + Pembrolizumab | Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma (Pembro-CORE) | Recruiting | DEU | 0 |
NCT04842877 | Phase II | DS-3201b | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma | Active, not recruiting | FRA | BEL | 0 |
NCT04866654 | Phase II | Nivolumab | Radiation Free Chemotherapy for Early Hodgkin Lymphoma (RAFTING) | Recruiting | POL | ITA | ESP | 0 |
NCT04871607 | Phase II | Basiliximab + Carmustine + Cytarabine + Etoposide + Filgrastim + Yttrium Y 90 Basiliximab | Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04875195 | Phase II | Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) | Active, not recruiting | USA | TUR | POL | ITA | FRA | CZE | CAN | BRA | 3 |
NCT04902443 | Phase I | Nivolumab + Pomalidomide | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | Recruiting | USA | 0 |
NCT04920383 | Phase I | ALPN-202 + unspecified PD-1 antibody | ALPN-202 With PD-1 Inhibition in Advanced Malignancies (NEON-2) | Terminated | USA | 0 |
NCT04938232 | Phase II | Ipilimumab + Nivolumab | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | Active, not recruiting | USA | 0 |
NCT05005442 | Phase II | MK-7684A | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | FRA | ESP | DNK | DEU | CAN | BRA | 4 |
NCT05008224 | Phase II | Bleomycin + Cyclophosphamide + Doxorubicin + Etoposide + Pembrolizumab + Prednisone + Procarbazine + Vincristine Sulfate Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) (KEYNOTE-C11) | Completed | USA | TUR | POL | ITA | ISR | FRA | ESP | CAN | AUS | 2 |
NCT05011058 | Phase II | CHR-3996 CHR-3996 + Valganciclovir | An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 5 |
NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05039073 | Phase II | Brentuximab vedotin + Nivolumab | Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors | Recruiting | USA | 0 |
NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | 2 | |
NCT05134740 | Phase I | MultiTAA-specific T cells | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). | Withdrawn | USA | 0 |
NCT05140382 | Phase II | AZD4573 | AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL | Completed | USA | SWE | ITA | GBR | FRA | AUS | 2 |
NCT05162976 | Phase I | Azacitidine + Nivolumab | CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | Active, not recruiting | USA | 0 |
NCT05179603 | Phase II | THOR-707 Pembrolizumab + THOR-707 | A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) | Terminated | ESP | ARG | 1 |
NCT05180097 | Phase II | Brentuximab vedotin + Pembrolizumab Cisplatin + Dexamethasone + Gemcitabine | Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | Recruiting | CAN | AUS | 0 |
NCT05181540 | Phase III | AB-205 | A Phase 3 Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) | Terminated | USA | 0 |
NCT05216835 | Phase Ib/II | AZD7789 | Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DNK | CAN | 0 |
NCT05253495 | Phase II | Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Vincristine Sulfate Cytarabine + Etoposide + Polatuzumab vedotin-piiq + Rituximab Cytarabine + Etoposide + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Cytarabine + Methotrexate + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Rituximab + Vinblastine Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL) | Recruiting | USA | 0 |
NCT05255601 | Phase Ib/II | Nivolumab + Relatlimab | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 0 |
NCT05272384 | Phase I | Decitabine and Cedazuridine + Nivolumab | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05279300 | Phase I | CS5001 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | AUS | 1 |
NCT05293912 | Phase I | SG2501 | SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma. | Recruiting | USA | 0 |
NCT05300282 | Phase Ib/II | Atezolizumab + Bendamustine + Gemcitabine + Vinorelbine Bendamustine + Gemcitabine + Vinorelbine | Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients (FIL_A-BEGEV) | Recruiting | ITA | 0 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Suspended | USA | 0 |
NCT05346809 | Phase II | Isatuximab | Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | Recruiting | USA | 0 |
NCT05352828 | Phase I | Bendamustine + Fludarabine ATLCAR.CD30 cells + Nivolumab | Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy (ACTION) | Active, not recruiting | USA | 0 |
NCT05355051 | Phase II | Azacitidine + Pembrolizumab | A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT05362773 | Phase I | MGD024 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT05400122 | Phase I | Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | Recruiting | USA | 0 |
NCT05404945 | Phase II | Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine Brentuximab vedotin + Pembrolizumab | Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | Recruiting | USA | 0 |
NCT05476770 | Phase I | Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT05502250 | Phase II | Cisplatin + Gemcitabine + Tislelizumab Tislelizumab | Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (HOVON164HL) | Recruiting | NLD | DNK | BEL | 0 |
NCT05508867 | Phase III | Gemcitabine Bendamustine MK-4280A | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) | Recruiting | USA | TUR | SWE | POL | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUS | ARG | 4 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05675410 | Phase III | Dacarbazine + Doxorubicin + Vinblastine Bleomycin + Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Vinblastine Bleomycin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Procarbazine + Vincristine Sulfate | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Recruiting | USA | CAN | 1 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05723055 | Phase II | Axatilimab + Nivolumab | Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (NAHL) | Suspended | USA | 0 |
NCT05883449 | Phase II | AB-101 + AFM13 Aldesleukin Cyclophosphamide + Fludarabine | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) | Recruiting | USA | 0 |
NCT05922904 | Phase II | Brentuximab vedotin + Dacarbazine + Doxorubicin + Pembrolizumab | PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05977673 | Phase II | Tislelizumab | Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy: a Phase II, Open-label Study (FIL_Tisle-HL) | Recruiting | ITA | 0 |
NCT06018129 | Phase Ib/II | GEN3017 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | Recruiting | USA | AUS | 0 |
NCT06045195 | Phase II | Pembrolizumab | Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma (Pembro-FLASH) | Not yet recruiting | DEU | 0 |
NCT06090864 | Phase Ib/II | ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine | ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells | Recruiting | USA | 0 |
NCT06120504 | Phase I | SGN-35T | A Safety Study of SGN-35T in Adults With Advanced Cancers | Recruiting | USA | GBR | ESP | DNK | CAN | 0 |
NCT06137144 | Phase Ib/II | AZD3470 | AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. (PRIMAVERA) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 1 |
NCT06150664 | Phase I | CTX-8371 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT06164275 | Phase II | Pembrolizumab Dacarbazine + Doxorubicin + Vinblastine | Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT06176690 | Phase I | C7R.CD30.CAR-EBVS T-cells | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | Not yet recruiting | USA | 0 |
NCT06254495 | Phase I | SGN-35C | A Safety Study of SGN-35C in Adults With Advanced Cancers | Recruiting | USA | ITA | DNK | 0 |
NCT06377566 | Phase II | Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Gemcitabine Dacarbazine Doxorubicin Pembrolizumab Brentuximab vedotin Vinorelbine Vinblastine | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT06395090 | Phase Ib/II | MK-7684A MK-4280 + Pembrolizumab Pembrolizumab + Vibostolimab MK-4280A | A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) | Recruiting | USA | 1 |
NCT06484920 | Phase II | Pembrolizumab + Tretinoin | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL | Recruiting | USA | 0 |
NCT06504394 | Phase II | MK-3475A | A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) | Recruiting | USA | POL | NZL | ESP | 1 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06521567 | Phase Ib/II | Cobolimab + Dostarlimab-gxly | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Not yet recruiting | USA | ITA | FRA | ESP | DNK | DEU | CZE | BRA | ARG | 1 |
NCT06617286 | Phase Ib/II | ATLCAR.CD30 cells | CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma | Not yet recruiting | USA | 0 |